




Searching News Database: CONTRAVE
HSMN NewsFeed - 2 Aug 2020
Varian to Combine with Siemens Healthineers in $16.4 Billion All-Cash Transaction
Varian to Combine with Siemens Healthineers in $16.4 Billion All-Cash Transaction
HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
HSMN NewsFeed - 2 Aug 2016
Meda Shareholders Representing Approximately 94% of Meda Shares Accept Mylan Offer
Meda Shareholders Representing Approximately 94% of Meda Shares Accept Mylan Offer
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 30 Oct 2015
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business
HSMN NewsFeed - 28 Aug 2015
Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo
Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo
HSMN NewsFeed - 12 May 2015
Sorin And Cyberonics Announce Executive Leadership Team For The New Company Upon Close Of Merger
Sorin And Cyberonics Announce Executive Leadership Team For The New Company Upon Close Of Merger
HSMN NewsFeed - 11 Aug 2014
Auxilium Pharmaceuticals, Inc. Appoints Andrew Saik Chief Financial Officer
Auxilium Pharmaceuticals, Inc. Appoints Andrew Saik Chief Financial Officer
HSMN NewsFeed - 17 Feb 2011
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
HSMN NewsFeed - 1 Feb 2011
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity
HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
HSMN NewsFeed - 10 Mar 2008
OREXIGEN(TM) Therapeutics Appoints Carol Baum as Vice President of Commercialization
OREXIGEN(TM) Therapeutics Appoints Carol Baum as Vice President of Commercialization
HSMN NewsFeed - 11 Dec 2007
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates Fourth Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 17 Oct 2007
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
OREXIGEN(TM) Therapeutics Initiates its Third Phase III Trial for Contrave(TM) to Treat Obesity
HSMN NewsFeed - 24 May 2006
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
Additional items found! 3

Members Archive contains
3 additional stories matching:
CONTRAVE
(Password required)
CONTRAVE
(Password required)